血液恶性瘤中的PI3K/Akt/mTOR信号通路-新的治疗可能性
Wojciech Wiese1, Julia Barczuk1, Olga Racinska1
1Department of Clinical Chemistry and Biochemistry, Medical University of Lodz, Mazowiecka 5, 92-215 Lodz, Poland.
酸丁醇-3激酶 (PI3K) /蛋白激酶B/哺乳动物目标的拉巴胺素 (PI3K/Akt/mTOR) 途径在血液癌症中至关重要. 针对这种途径的抑制剂为白血病治疗提供了新的治疗途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血液恶性瘤带来了重大的治疗挑战.
- PI3K/Akt/mTOR通路是细胞功能不可或缺的一部分,其失调驱动致癌.
- 在各种白血病中观察到这种途径的过度活化,促进癌细胞的生长和治疗抵抗力.
研究的目的:
- 审查PI3K/Akt/mTOR信号通路在血液恶性瘤中的作用.
- 收集关于用于治疗白血病的PI3K/Akt/mTOR抑制剂的信息.
主要方法:
- 在血液癌症中PI3K/Akt/mTOR通路的文献综述.
- 对现有和新兴PI3K/Akt/mTOR抑制剂的分析.
- 对这些抑制剂的临床前和临床数据的评估.
主要成果:
- 在白血病中,PI3K/Akt/mTOR通路经常失调,导致疾病进展.
- 自2014年以来,已批准的PI3K/Akt/mTOR抑制剂已经显示出有效性.
- 新的抑制剂正在研究中,在临床前和临床环境中显示出潜力.
结论:
- PI3K/Akt/mTOR通路是血液恶性瘤的一个关键标.
- 向抑制这种途径代表了白血病的有希望的治疗策略.
- 对新型抑制剂的持续研究可能会导致改善治疗结果.
更多相关视频
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
Regulation of Angiogenesis and Blood Supply
